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euroPean situation
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Objectives: In the last decade awareness has been raised due to unsafe and 
dangerous devices entering the European market, putting patient safety at stake. 
Consequently, evidence requirements may not be enough to ensure a high-quality 
and safe provision of medical devices in Europe.This research aims at exploring the 
authorization and reimbursement processes and the associated evidence require-
ments comparing four high-impact regions Europe, United States, Australia and 
Canada. MethOds: First, we performed a literature search about the authorization 
and reimbursement in the four high-impact regions. Second, seven high-risk medi-
cal devices were chosen as examples and current authorization and reimbursement 
status were assessed. Information was extracted from publicly available summaries, 
from PubMed, and from the clinical trial database (clincialtrial.gov), supplemented by 
the worldwideweb. Results: The evidence required for the authorization and reim-
bursement processes clearly differs in the four high-impact regions. All seven devices 
have been authorized in Europe, three in Australia, one in the United States, and one 
in Canada. Currently none of the seven devices is recommended for reimbursement 
in the four high-impact regions. cOnclusiOns: Looking at the difference in evidence 
requirements, more harmonization, transparency and specific regulations are needed 
worldwide for the authorization and reimbursement of high-risk medical devices to 
ensure a high-quality and safe provision.
PHP15
overview of external reference Pricing systems in euroPe
Rémuzat C.1, Urbinati D.2, Roïz J.3, Kornfeld A.1, Toumi M.4
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Objectives: External reference pricing (ERP) is one of most common cost-contain-
ment tools used to reduce prices for in-patent pharmaceuticals in the European 
Union Member States (MS). The objective of this project was to provide an overview 
of ERP systems, both on processes and potential issues related to ERP systems in 31 
European countries (28 EU MS, Iceland, Norway and Switzerland) (performed for the 
EU Commission). MethOds: A systematic structured literature review and consulta-
tion of representatives of competent authorities and international organizations were 
conducted to identify and characterize the use of ERP, to describe its impacts on the 
prices of pharmaceuticals and to discuss possible cross-country coordination issues 
in EU MS. Results: All selected countries apply ERP except the UK and Sweden and 
23 countries use ERP as main systematic criterion. ERP is based on legislated pricing 
rules with different levels of accuracy in the majority of European countries using 
ERP. ERP is applied either to all marketed drugs or to specific categories of medicines, 
mainly used for publicly reimbursed medicines. The number of reference countries 
included in the basket varies from 1 to 31. There is a great variation in calculation 
methods used to compute the price; 15 countries use average price, 7 countries use the 
lowest price, and 7 countries use other calculation methods. Among reported limita-
tions of ERP application are reliable sources of price information, price heterogeneity, 
exchange rate volatility, and hidden discounts. Spill-over effects on other countries 
and downward price convergence have often been argued leading to pricing strategies 
from pharmaceutical companies. cOnclusiOns: While ERP is widely used in Europe, 
processes and available price information vary from one country to another that may 
limit ERP application. Moreover, ERP spill-over effect is a major concern of pharmaceu-
tical firms leading to implementation of the so-called “launch sequence strategies”.
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Objectives: In Korea, the positive list system (PLS) was introduced in 2007 to 
ensure the good value for money in pharmaceutical expenditure. This study aims 
to investigate factors that are most influential in reimbursement decisions under 
the PLS. MethOds: To assess the 5 years operations and compare the results 
before and after the PLS, we analyzed the drug prices submitted from the com-
panies, the reimbursement decisions made by Pharmaceutical Benefit Coverage 
Assessment Committee (PBCAC). We extracted data from published evaluation 
reports, PBCAC meeting minutes, and internal documents of Health Insurance 
Review and Assessment Service. Results: Under the PLS, 71% of submitted drugs 
were recommended for reimbursement during January 2007- April 2012. For sub-
missions demonstrated superiority or non-inferiority in clinical benefit, 79% of 
submissions were decided to be reimbursed. However, submissions with inferiority 
or uncertainties in clinical benefit were rejected regardless of the price. Comparing 
the negotiated price under the PLS to the relative price under the negative system, 
the negotiated price was 85% of the relative price. The probability of recommenda-
tion was high when ICER was under the GDP per capita, nevertheless submissions 
with high uncertainty in cost-effectiveness were rejected. Submissions which had 
low uncertainty and products for severe diseases or rare diseases were recom-
mended for reimbursement despite ICER was high. cOnclusiOns: This study 
confirmed clinical benefit was the main driver of the reimbursement decision 
making. Not only clinical benefit and cost-effectiveness but the disease sever-
ity, the uncertainty of evidence and reimbursement in other countries were also 
considered in the reimbursement decision making process. In addition, the drug 
prices were reduced a little after PLS introduced compared to those under the 
negative list system.
reimbursement decisions. Our objective was to evaluate the lag between a drug’s 
FDA approval and the publication of the first published CUA evaluating the prod-
uct. MethOds: We used the FDA’s website to identify newly-approved drugs from 
2000-2010 (n= 342). For each drug, we searched the Tufts Medical Center Cost-
Effectiveness Analysis Registry and the NHS Economic Evaluation Database for CUAs 
evaluating the drug for the corresponding FDA-approved indication. We included 
drugs with a corresponding CUA in our dataset. When multiple CUAs for a drug 
were available, we included the CUA with the earliest publication date. We used 
multivariate regression to determine factors associated with time to CUA publica-
tion (years). Independent variables included drug approval year, study funder, i.e., 
whether the CUA was supported by industry, and whether the FDA assigned the 
drug priority review status. Results: One hundred and fifty-six (45.6%) drugs in 
our sample had a corresponding CUA. Average time to CUA publication was 4 years 
(standard deviation 2.3 years). We divided drug approvals into three time inter-
vals; 2000-2002 (mean time to CUA publication= 5.3; SD= 2.4), 2003-2006 (mean= 3.9; 
SD= 2.1) and 2007-2010 (mean= 2.4; SD= 0.97). We found that compared to CUAs for 
drugs approved from 2000-2002, time to CUA publication was 1.5 years shorter for 
drugs approved from 2003-2006 (p< 0.001) and 3 years shorter for drugs approved 
from 2007-2010 (p< 0.0001). Source of study support and FDA priority review sta-
tus were not significantly associated with time to publication cOnclusiOns: For 
FDA-approved drugs with a corresponding CUA, we found a substantial time lag 
between FDA approval and CUA publication, suggesting that decision-makers are 
making important drug coverage and reimbursement decisions without published 
cost-effectiveness evidence available. However, the time to CUA publication appears 
to have declined over time.
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Ma F.F., Wu J., Zhao M.Y.
Tianjin University, Tianjin, China
Objectives: To measure the trend of price level for anti-infective drugs in Tianjin, 
China from 2006 to 2010 using multiple index methods and to explore measurement 
bias induced by index methods and measurement units. MethOds: Data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
database from 2006 to 2010. Laspeyres, Paasches, Fisher and chained Fisher index 
methods were employed to measure the price level. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation and manufacturer). Units of quantity and price were 
defined as per DDD (Defined Daily Dose), per milligram of active ingredient, and per 
minimum unit separately to calculate the indices. Results: At product level, 367 
constantly used products (26% of total 1422 products) were included in unchained 
indices and 1041 products (73% of total products) were included in chained Fisher 
indices. The results of multiple indices consistently indicated that the price level 
decreased and the decreasing range indicated by different index methods were 
from 16% (Laspeyres-unit index at molecule level) to 27% (Laspeyres-DDD index at 
product level). The price indices at molecule level decreased slower than the coun-
terparts at product level (22% vs. 25% in chained Fisher-DDD index). At molecule 
level, price indices based on per DDD decreased faster than per mg and per unit 
(22%, 21% and 18% in chained Fisher). Laspeyres indices decreased slower than 
Paasches at molecule level while the contrary was the case at product level. The 
results from chained Fisher and unchained counterparts were similar (25% vs. 26% 
at product level). cOnclusiOns: The price level of anti-infective drugs decreased 
heavily in Tianjin, China. The chained indices were similar to the unchained coun-
terparts which suggested that the price of newer and older products decreased at 
similar rate.
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Objectives: To establish performance evaluation model of the Essential Medicine 
System in China based on Data Envelopment Analysis(DEA), evaluate the relative 
efficiency of essential medicines system and analysis the main problem and impact 
factors on it. MethOds: 15 counties in Sichuan province were selected by stratified 
sampling as Decision Making Units(DMUs); for each county, 30% primary health 
care facilities, totally 284 facilities were involved as sample. Questionnaire survey 
was conducted to collect data of input and output indicators in 2010 and 2011 from 
sample facilities. 3 input indicators and 4 output indicators were set based on lit-
erature review, WHO’s National Drug Policies Monitoring Indicators and experiential 
principle of DEA. Excel 2007 was used to encode data, DEAP 2.1 software was used 
to conduct CRS - CCR and VRS - BCC Data Envelopment Analysis, SPSS16.0 was used 
to conduct T-test and multiple linear regression analysis to exam the statistic dif-
ference between 2010 and 2011, and the influencing factors of efficiency. Results: 
For input indicators, the average special funds of Essential Medicine System(x1) in 
15 counties was raised from 0.52 million US$ in 2010 to 0.69 million US$ in 2011
；the average number of essential medicines(x2) and drug delivery companies(x3) 
raised as well. For output indicators, average outpatient cost per visit(y1) and inpa-
tient cost per admission(y2) decreased, while the outpatient visit times(y3) and 
discharge numbers(y4) kept no increasing as expected. The overall efficiency of 
Essential Medicines System in Sichuan province in two years were in relatively 
high level(0.908 in 2010 and 0.832 in 2011). Analysis on technical efficiency, scale 
efficiency, and return to scale showed the main existing problem was insufficient 
utilization of input health care resource. cOnclusiOns: The effectiveness of imple-
mentation of Nation Essential Medicine System has been displayed, but health 
care resources should be adjusted and utilized rationally to improve the overall 
efficiency.
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Objectives: Since 1992, the Food and Drugs Administration (FDA) accelerated 
approval pathway has enabled market entry of drugs for serious conditions based 
on a surrogate endpoint that is likely to predict clinical benefit with confirma-
tory trials to be completed post-approval. However, five drugs have since been 
withdrawn or severely restricted following accelerated approval due to lack of effi-
cacy (bevacizumab, [indication: breast cancer; withdrawn 2011; approved 2009], 
amifostine [indication: renal toxicity; withdrawn: 2006; approved: 1996], gefitinib 
[withdrawn: 2005; approved: 2003), safety concerns (gemtuzumab, withdrawn 2010; 
approved 2000), or lack of confirmatory trial data (celecoxib, indication: Familial 
Adenop Polymatosis [FAP], withdrawn: 2011, approved 1999), leading to criticisms 
that this pathway allows drugs to enter the market prior to their efficacy and safety 
being adequately demonstrated. This research aims to evaluate these criticisms 
by comparing how the drugs were assessed by the European Medicines Agency 
(EMA). MethOds: EMA and FDA evaluations of these drugs were sourced; the 
approval decision, date, and rationale were compared, alongside any post-approval 
restrictions/withdrawals. Results: EMA appraisal information was publically avail-
able for bevacizumab, gefitinib, gemtuzumab, and celecoxib. Gemtuzumab (EMA 
refused, 2008) and gefitinib (EMA submission withdrawn 2005 after failing Phase III 
trial) were not granted EMA licences in the FDA-approved indications. In contrast, 
bevacizumab (2007) and celecoxib (2003) were EMA-approved with the same data 
package used to gain approval by the FDA. In 2011, celecoxib was withdrawn for 
FAP in both Europe and US due to lack of confirmatory trial data. However, bevaci-
zumab was EMA approved a year earlier than the FDA and has not been withdrawn 
by the EMA in this indication. cOnclusiOns: FDA accelerated approval pathway 
criticism due to post-approval drug withdrawals may be overstated, as the EMA 
approved two of the five drugs subsequently withdrawn by the FDA, one of which 
the EMA has not withdrawn.
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estimation of cHange in PrescriPtion Drug exPenDitures on tHe 
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Heo J.H.1, Rascati K.L.2, Lee E.K.3
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Objectives: A reference pricing system is a policy strategy that sets a reim-
bursement level or reference price for a group of therapeutically interchange-
able drugs, i.e. the reference group. A patient is responsible for any difference 
between the reference price and the price of a more costly drug. The purpose of 
this study was to estimate future prescription drug expenditures after implemen-
tation of the reference pricing system in South Korea. MethOds: Korean national 
health insurance data collected for January, April, July, and October in 2011 were 
obtained from the Health Insurance Review and Assessment Service. All medica-
tions were included to estimate drug expenditures, except patented drugs and 
orphan drugs. A reference group was defined as the category including drugs with 
same ingredient or same therapeutic class. Possible scenarios after the introduc-
tion of the reference pricing system, such as a copay deduction program for only 
drugs below the reference price by the government, price lowering by companies 
and changes in prescribing patterns, were included in the model. Results: A 
base-line copay rate of 20.4% was calculated. When a reference price was set 
at the average price of drugs in the reference group, patient co-payment rates 
were estimated to increase to 23.9%. However, when we assumed that companies 
reduce the price by 5% and prescribers changed 10% of prescriptions to avoid 
patients paying additional co-payments, co-payment rates were estimated to be 
22.9%. In addition, the copay deduction could help decrease co-payment rates to 
19.6%. cOnclusiOns: Reference pricing system can contribute to a reduction 
in prescription medication expenditures for third-party payers. The co-payment 
for patients could be increased by moving additional financial burden from the 
insurer to patients. However, an increase in co-payment rates could be limited and 
total drug expenditures could be reduced by copay discounts, medication price 
reductions or prescribing changes.
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Objectives: This study evaluates pharmaceutical companies pricing strategies 
after generic entry into the New Zealand market in the period 2007-2012, and its 
effects on drug utilization and expenditures. MethOds: Market data derived from 
IMSHealth. Data include active ingredient, route, dosage form, strength, brand/
generic status, prescription drug (Rx)/over-the-counter status, date of market entry, 
ex-manufacturer standard unit sales, and ex-manufacturer NZ dollars sales. NZ$ 
were adjusted to 2012 using the NZ consumer price index. Study sample includes the 
37 products of the top 125 products by sales in the period 2007-2012 that experienced 
generic entry during the study period. Results: Sales of products in the top 125 by 
sales amounted NZ$3.1 billion; 46.6% of the overall NZ market. Brands accounted for 
95.8% of the expenditures. The average ex-manufacturer price per standard unit was 
NZ$55.9 (95%CI: NZ$43.8-67.9) for Rx, and NZ$ 685.8 for therapeutic biologics (95%CI: 
NZ$482.3-889.2). The median price at generic entry date was 27.4% of the median 
brand price. The median price at generic entry date of study sample was NS$1.18 
per unit for brands and NS$0.32 for generics. In 2012, the median price per unit was 
down to NZ$0.83 and NZ$0.22 for brands and generics, respectively. Standard unit 
sales increased on average 14% (95% CI 7%-21%) after first year of generic entry. 
Several brand products (clopidogrel, letrozole, omeprazole, pantoprazole) were dis-
continued after generic entry. cOnclusiOns: Generic entry resulted in an average 
30% reduction in the average drug price. Brand companies either reduced the brand 
price to match generic prices, or maintained the brand price at levels immediately 
before generic market entry. The first strategy resulted in the brand keeping large 
PHP17
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Objectives: To reveal the main causes of non-compliance for technology incorpo-
ration requests into the Brazilian Public Health System (SUS) for the period of 2012 
and 2013. MethOds: This was a descriptive cross-sectional study. The analysis was 
performed using the database of National Committee for Technology Incorporation 
(CONITEC) submitted applications for incorporation in the years 2012 and 2013. The 
CONITEC, which belongs to the Ministry of Health of Brazil, is responsible for the 
incorporation, exclusion or alteration of new medicines, procedures and products 
on the public health system. The presentation of economic evaluation by applicants 
(economic study and a budget impact analysis) is necessary to enable the analysis of 
the proposed requirements. Results: Out of the 142 external (outside the Ministry 
of Health) requests submitted for analysis, 56 (39%) were non-compliant, 50 (89%) 
of them were due to problems in the economic evaluation. Out of the economi-
cally non-compliant, 16 (32%) presented problems in the economic study only and 
32 (64%) of them presented problems in both items. The main problems observed 
were not submitting an economic study, not submitting the economic model used 
in the study, and presenting an economic study using a different perspective than 
the one of SUS. cOnclusiOns: The high percentage of non-compliance due to the 
economic evaluation points out the difficulty faced in completing these studies. It 
is important to invest in initiatives, human resources, training and spreading of 
economic evaluation knowledge which enables clarifying the required criteria for 
applying for an incorporation request.
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Progress in PersonalizeD meDicine is slower tHan some HaD 
exPecteD, Partly because of tHe science anD Partly because of 
insufficient economic incentives, Particularly for investing in 
molecular Diagnostics (mDx)
Mallinson M.
Access Partnership, London, UK
Objectives: Ten years after completion of the Human Genome Project, progress 
towards making personalized medicine a reality has been slower than expected. 
This paper seeks to identify how evidence has been generated by critically evaluat-
ing successful MDx case studies, and, to the extent possible, identify any lessons 
from them. MethOds: A literature review identified nine examples of success 
where diagnostic tests are bringing personalized medicine into clinical practice 
with positive health and economic impact for patients, health care systems, and 
manufacturers. Results: Each case demonstrates that a companion MDx can 
provide information to patients and health care providers; allow for a targeting of 
treatments or other interventions to a subset of the population despite differences 
in whether they are prognostic, predictive, or used for monitoring; offer the potential 
for the health system to deliver more health gain. cOnclusiOns: There is a diver-
sity of approaches in developing MDx and the range of challenges posed both by the 
science and in acceptance and use. Moreover, because of the great potential value of 
personalized medicine for patients and health systems alike, there is a compelling 
rationale that both payers and the public sector should help fund research on the 
clinical effectiveness of MDx.
PHP20
assessment of PHarmaceutical ProDucts aPProveD by tHe uniteD 
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MCPHS University, Boston, MA, USA
Objectives: In spite of the globalization of the pharmaceutical industry, differences 
exist in the number and characteristics of the pharmaceutical products available 
in each country. This study compared the pharmaceutical products approved in 
the US and registered in Peru as of December, 2013, and assessed differences in 
approvals of chemical entities, therapeutic biologics and orphan drugs, and generic 
entry. MethOds: Information about pharmaceutical products approved in the US 
and Peru was obtained from the US Food and Drug Administration (FDA), and the 
General Directory of Medicines, Supplies, and Drugs of Peru (DIGEMID), respec-
tively. Descriptive statistics and chi-square tests were performed in the analysis. 
Significant level was set at 0.05. Results: A total of 2,409 approved pharmaceutical 
products were listed by the FDA as of December, 2013 of which 763 (31.7%) were 
also registered by DIGEMID, including 39.1% of generic multisource products and 
25.1% of brand single source products. A total of 112 biologic products were listed by 
the FDA and 64 (57.1%) were also registered in Peru. There were 368 products with 
orphan indications approved by the FDA and 112 (30.4%) were also registered in Peru. 
Generic competition was available for 46.8% of the products approved by the FDA 
and 57.8% of the products approved by DIGEMID (p< 0.001). cOnclusiOns: Peru 
has substantially less pharmaceutical products approved than the US, especially 
for brand products without generic competition and orphan drugs. The highest 
percentage of products approved in both countries corresponded to therapeutic bio-
logics. Part of the differences in drug approvals can be explained by variations in the 
epidemiological profile of both countries. The relatively small size of the Peruvian 
pharmaceutical market and limited purchasing power may result in reduced incen-
tives for pharmaceutical companies to register new molecular entities and products 
for orphan diseases in Peru.
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